Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum to: Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.
Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, Oggioni R, Pasetti GS, Romero M, Tognoni G, Latini R, Gattinoni L. Masson S, et al. Among authors: bernasconi r. Intensive Care Med. 2015 Sep;41(9):1736. doi: 10.1007/s00134-015-3982-z. Intensive Care Med. 2015. PMID: 26183490 No abstract available.
Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Latini R, Masson S, Jeremic G, Luvarà G, Fiordaliso F, Calvillo L, Bernasconi R, Torri M, Rondelli I, Razzetti R, Bongrani S. Latini R, et al. Among authors: bernasconi r. J Cardiovasc Pharmacol. 1998 Apr;31(4):601-8. doi: 10.1097/00005344-199804000-00020. J Cardiovasc Pharmacol. 1998. PMID: 9554811
Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Masson S, Masseroli M, Fiordaliso F, Calvillo L, D'Aquila S, Bernasconi R, Garrido G, Torri M, Razzetti R, Bongrani S, Latini R. Masson S, et al. Among authors: bernasconi r. J Cardiovasc Pharmacol. 1999 Sep;34(3):321-6. doi: 10.1097/00005344-199909000-00001. J Cardiovasc Pharmacol. 1999. PMID: 10470987
Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial.
Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, Favero C, Franzosi MG, Serra D, Lucci D, Bianchini F, Bernasconi R, Maggioni AP, Nicolosi G, Porcu M, Tognoni G, Tavazzi L, Marchioli R. Finzi AA, et al. Among authors: bernasconi r. Am Heart J. 2011 Feb;161(2):338-343.e1. doi: 10.1016/j.ahj.2010.10.032. Am Heart J. 2011. PMID: 21315217 Free article. Clinical Trial.
135 results